A GABBR2 gene variant modifies pathophysiology in Huntington’s disease

April L Philpott, Paul B Fitzgerald, Neil W Bailey, Andrew Churchyard, Nellie Georgiou-Karistianis, Tarrant D.R. Cummins

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Striatal degeneration in Huntington’s disease (HD) causes changes in cortico-subcortical pathways. Transcranial magnetic stimulation (TMS) is a valuable tool for assessing pathophysiology within these pathways, yet has had limited application in HD. As cortico-subcortical pathways are largely mediated by GABA and dopamine receptor genes, understanding how these genes modulate neurophysiology in HD may provide new insights into how underlying pathology maps onto clinical phenotype. Twenty-nine participants with HD underwent motor cortex stimulation, while corticospinal excitability, cortical inhibition and intracortical facilitation were indexed via peripheral electromyography. Single-nucleotide polymorphism mapping was performed across six genes that are known to modulate cortico-subcortical pathways (GABRA2, GABBR1, GABBR2, DRD1, DRD2, DRD4). Genetic associations with six TMS measures and age at onset were investigated. Our hierarchical multiple regression analysis, controlling for CAG and age, revealed that a GABBR2 variant, predicted to be disease-causative, was significantly associated with corticospinal excitability at corrected levels. A subsequent uncorrected exploratory analysis revealed associations between GABBR2, GABRA2 and DRD2 variants with TMS measures of corticospinal excitability and cortical inhibition in HD, as well as with age at onset. Our findings support the notion that uncovering genetic associations with pathophysiological measures and age at onset is an important way forward in terms of generating meaningful biomarkers with diagnostic and prognostic sensitivity, and identifying novel human-validated targets for future clinical trials.
Original languageEnglish
Pages (from-to)8-13
Number of pages6
JournalNeuroscience Letters
Volume620
DOIs
Publication statusPublished - 4 May 2016

Keywords

  • Age at onset
  • corticoal excitability
  • Dopamine
  • GABA
  • Single-nucleotide polymorphism
  • Transcranial magnetic stimulation

Cite this

@article{c6d2d204f7c34d7781067b4859582e75,
title = "A GABBR2 gene variant modifies pathophysiology in Huntington’s disease",
abstract = "Striatal degeneration in Huntington’s disease (HD) causes changes in cortico-subcortical pathways. Transcranial magnetic stimulation (TMS) is a valuable tool for assessing pathophysiology within these pathways, yet has had limited application in HD. As cortico-subcortical pathways are largely mediated by GABA and dopamine receptor genes, understanding how these genes modulate neurophysiology in HD may provide new insights into how underlying pathology maps onto clinical phenotype. Twenty-nine participants with HD underwent motor cortex stimulation, while corticospinal excitability, cortical inhibition and intracortical facilitation were indexed via peripheral electromyography. Single-nucleotide polymorphism mapping was performed across six genes that are known to modulate cortico-subcortical pathways (GABRA2, GABBR1, GABBR2, DRD1, DRD2, DRD4). Genetic associations with six TMS measures and age at onset were investigated. Our hierarchical multiple regression analysis, controlling for CAG and age, revealed that a GABBR2 variant, predicted to be disease-causative, was significantly associated with corticospinal excitability at corrected levels. A subsequent uncorrected exploratory analysis revealed associations between GABBR2, GABRA2 and DRD2 variants with TMS measures of corticospinal excitability and cortical inhibition in HD, as well as with age at onset. Our findings support the notion that uncovering genetic associations with pathophysiological measures and age at onset is an important way forward in terms of generating meaningful biomarkers with diagnostic and prognostic sensitivity, and identifying novel human-validated targets for future clinical trials.",
keywords = "Age at onset, corticoal excitability, Dopamine, GABA, Single-nucleotide polymorphism, Transcranial magnetic stimulation",
author = "Philpott, {April L} and Fitzgerald, {Paul B} and Bailey, {Neil W} and Andrew Churchyard and Nellie Georgiou-Karistianis and Cummins, {Tarrant D.R.}",
year = "2016",
month = "5",
day = "4",
doi = "10.1016/j.neulet.2016.03.038",
language = "English",
volume = "620",
pages = "8--13",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier",

}

A GABBR2 gene variant modifies pathophysiology in Huntington’s disease. / Philpott, April L; Fitzgerald, Paul B; Bailey, Neil W; Churchyard, Andrew; Georgiou-Karistianis, Nellie; Cummins, Tarrant D.R.

In: Neuroscience Letters, Vol. 620, 04.05.2016, p. 8-13.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - A GABBR2 gene variant modifies pathophysiology in Huntington’s disease

AU - Philpott, April L

AU - Fitzgerald, Paul B

AU - Bailey, Neil W

AU - Churchyard, Andrew

AU - Georgiou-Karistianis, Nellie

AU - Cummins, Tarrant D.R.

PY - 2016/5/4

Y1 - 2016/5/4

N2 - Striatal degeneration in Huntington’s disease (HD) causes changes in cortico-subcortical pathways. Transcranial magnetic stimulation (TMS) is a valuable tool for assessing pathophysiology within these pathways, yet has had limited application in HD. As cortico-subcortical pathways are largely mediated by GABA and dopamine receptor genes, understanding how these genes modulate neurophysiology in HD may provide new insights into how underlying pathology maps onto clinical phenotype. Twenty-nine participants with HD underwent motor cortex stimulation, while corticospinal excitability, cortical inhibition and intracortical facilitation were indexed via peripheral electromyography. Single-nucleotide polymorphism mapping was performed across six genes that are known to modulate cortico-subcortical pathways (GABRA2, GABBR1, GABBR2, DRD1, DRD2, DRD4). Genetic associations with six TMS measures and age at onset were investigated. Our hierarchical multiple regression analysis, controlling for CAG and age, revealed that a GABBR2 variant, predicted to be disease-causative, was significantly associated with corticospinal excitability at corrected levels. A subsequent uncorrected exploratory analysis revealed associations between GABBR2, GABRA2 and DRD2 variants with TMS measures of corticospinal excitability and cortical inhibition in HD, as well as with age at onset. Our findings support the notion that uncovering genetic associations with pathophysiological measures and age at onset is an important way forward in terms of generating meaningful biomarkers with diagnostic and prognostic sensitivity, and identifying novel human-validated targets for future clinical trials.

AB - Striatal degeneration in Huntington’s disease (HD) causes changes in cortico-subcortical pathways. Transcranial magnetic stimulation (TMS) is a valuable tool for assessing pathophysiology within these pathways, yet has had limited application in HD. As cortico-subcortical pathways are largely mediated by GABA and dopamine receptor genes, understanding how these genes modulate neurophysiology in HD may provide new insights into how underlying pathology maps onto clinical phenotype. Twenty-nine participants with HD underwent motor cortex stimulation, while corticospinal excitability, cortical inhibition and intracortical facilitation were indexed via peripheral electromyography. Single-nucleotide polymorphism mapping was performed across six genes that are known to modulate cortico-subcortical pathways (GABRA2, GABBR1, GABBR2, DRD1, DRD2, DRD4). Genetic associations with six TMS measures and age at onset were investigated. Our hierarchical multiple regression analysis, controlling for CAG and age, revealed that a GABBR2 variant, predicted to be disease-causative, was significantly associated with corticospinal excitability at corrected levels. A subsequent uncorrected exploratory analysis revealed associations between GABBR2, GABRA2 and DRD2 variants with TMS measures of corticospinal excitability and cortical inhibition in HD, as well as with age at onset. Our findings support the notion that uncovering genetic associations with pathophysiological measures and age at onset is an important way forward in terms of generating meaningful biomarkers with diagnostic and prognostic sensitivity, and identifying novel human-validated targets for future clinical trials.

KW - Age at onset

KW - corticoal excitability

KW - Dopamine

KW - GABA

KW - Single-nucleotide polymorphism

KW - Transcranial magnetic stimulation

U2 - 10.1016/j.neulet.2016.03.038

DO - 10.1016/j.neulet.2016.03.038

M3 - Article

VL - 620

SP - 8

EP - 13

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

ER -